FeesSafety
Pluang+

BrainStorm advances Phase 3b trial for ALS therapy NurOwn, reports Q3 2026 financials with reduced net loss.

Company Fundamentals
16 Nov 2026, 23:01 WIB
PRNewsWire
View Source
Bullish
BrainStorm advances Phase 3b trial for ALS therapy NurOwn, reports Q3 2026 financials with reduced net loss.

BrainStorm Cell Therapeutics announced progress toward initiating the Phase 3b ENDURANCE trial for its ALS treatment NurOwn, supported by an FDA Special Protocol Assessment. The company appointed former FDA official Professor Peter J. Pitts as Executive Chairman to lead regulatory and strategic efforts. Financially, BrainStorm reported a Q3 2026 net loss of $1.7 million, an improvement from $2.1 million in Q3 2025, with reduced R&D and administrative expenses. The company continues to engage with regulators and partners while advancing its stem cell therapy pipeline for neurodegenerative diseases.

BrainStorm Cell Therapeutics' Q3 2026 financial results and corporate update provide context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 17, 2026 03:31 WIB: Out of 150 priced health-sector US stocks, 31 rose and 118 fell today. Among notable movers, SLS traded at USD 7.36 with a 6.42% decline and a strong buy interest of 96% on Pluang, contrasting with ARWR at USD 44.78 down 6.28% and SANA at USD 1.90 down 6.19%, which saw 100% buy orders and a longer typical hold time of 27 days.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App